Thursday, February 1, 2018

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

Alkermes plc Logo- New Medicine for Treating Major Depressive Disorder Supported by Comprehensive Efficacy and Safety Data Package From More Than 1,500 Patients - DUBLIN, Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA) to the...




from PR Newswire: //http://ift.tt/2DRsJ2V
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)